Rousset-Jablonski, Christine http://orcid.org/0000-0001-7087-5687
Lortal, Barbara
Lantheaume, Sophie
Arnould, Laurent
Simon, Hélène
Tuszynski, Anne-Sophie
Courtier, Mélanie
Debbah, Soukayna
Lefrançois, Marc
Balbin, Sita
Kably, Anne-Sophie
Toledano, Alain
Funding for this research was provided by:
Roche
Article History
Received: 19 October 2023
Accepted: 24 March 2024
First Online: 18 April 2024
Declarations
:
: All authors have received honorarium from Roche SAS. H Simon declared consulting fees from Lily and Roche; honoraria for lectures from Astra Zeneca, Amgen, Daïichi Sankyo, Lilly, and Viatris; support for attending meeting/travels from Novartis, Eisai, Pfizer, Lilly, and Gilead; and participation on data safety monitoring from Daïichi Sankyo and Roche. M Lefrançois declared consulting fees from Roche (through a contract between Roche and CM International (also known as CMI), to whom payments were made and of which he is an employee) and stock options from CMI group, the parent company of CM International. S Debbah declared consulting fees from Roche (through a contract between Roche and CM International (also known as CMI), to whom payments were made and of which he is an employee). M Courtier declared grants from Roche (between Jeune et Rose Association and Roche). C Rousset-Jablonski declared lectures, paid to her institution from Organon, Theramex, Novartis, and paid consulting fees to her institution from Theramex and Gedeon Richter.